ADA and esophageal squamous cell carcinoma: Post baseline, there were 9 (8.0%) patients who were ADA positive to durvalumab (BTC, n = 6 [14.3%]; ESCC, n = 2 [4.9%]; HNSCC, n = 1 [3.4%]).